Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18769708 | ASSAY METHOD OF ANTIBODY | July 2024 | March 2025 | Allow | 8 | 1 | 0 | No | No |
| 18616550 | DETECTION OF ANTI-p53 ANTIBODIES | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18585679 | METHOD OF DETERMINING AN IMMUNOGENIC RESPONSE CHARACTERISTIC OF A CHEMICAL SUBSTANCE | February 2024 | March 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18414339 | KITS AND METHODS TO DISTINGUISH FALSE LABOR AND TRUE LABOR | January 2024 | December 2024 | Allow | 11 | 2 | 0 | No | No |
| 18406399 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | January 2024 | April 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18392925 | IMMUNO-BASED RETARGETED ENDOPEPTIDASE ACTIVITY ASSAYS | December 2023 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18482286 | KITS AND METHODS FOR PREDICTION AND TREATMENT OF PREECLAMPSIA | October 2023 | November 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18467302 | ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ANDRENDOMEDULLIN | September 2023 | November 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18367823 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | September 2023 | October 2023 | Allow | 1 | 1 | 0 | No | No |
| 18353683 | COMPOSITIONS AND METHODS FOR ASSAYING PLATELET REACTIVITY AND TREATMENT SELECTION | July 2023 | December 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18340235 | ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ANDRENDOMEDULLIN | June 2023 | October 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18330550 | METHODS OF DETECTING ANTI-LEPTIN NEUTRALIZING ANTIBODIES | June 2023 | May 2025 | Abandon | 23 | 1 | 0 | Yes | No |
| 18315230 | SYSTEMS AND METHODS TO IDENTIFY AND TREAT SUBJECTS AT RISK FOR OBSTETRICAL COMPLICATIONS | May 2023 | January 2025 | Allow | 20 | 1 | 1 | No | No |
| 18173604 | Type X Collagen Assays and Methods of Use Thereof | February 2023 | October 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18110229 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | February 2023 | July 2023 | Allow | 5 | 1 | 0 | No | No |
| 18164058 | HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNP | February 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18067622 | BIOMARKERS FOR DIAGNOSING IMPLANT RELATED RISK OF IMPLANT REVISION DUE TO ASEPTIC LOOSENING | December 2022 | July 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17994029 | MARKER AND PRODUCT FOR AUXILIARY DIAGNOSIS OF VALVULAR HEART DISEASE (VHD) | November 2022 | April 2024 | Abandon | 17 | 2 | 1 | Yes | No |
| 18058683 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | November 2022 | May 2025 | Abandon | 30 | 2 | 0 | No | No |
| 17992664 | Analyte Test Strip Assays, and Test Strips and Kits for Use in Practicing the Same | November 2022 | February 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18053028 | Immunoassay for Detecting Zika Virus Infection | November 2022 | September 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18049596 | ESTIMATING CELLULAR POPULATIONS | October 2022 | January 2025 | Abandon | 27 | 1 | 1 | No | No |
| 17970775 | METHODS FOR ANALYSING A URINE SAMPLE | October 2022 | March 2025 | Abandon | 28 | 1 | 1 | No | No |
| 17962125 | SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID | October 2022 | April 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17957853 | COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASE | September 2022 | December 2024 | Allow | 27 | 2 | 0 | No | No |
| 17822475 | ENCAPSULATED REAGENTS AND METHODS OF USE | August 2022 | July 2024 | Allow | 23 | 1 | 1 | No | No |
| 17897026 | METHOD AND DEVICE FOR DISCRIMINATING BETWEEN VIRAL AND BACTERIAL INFECTIONS | August 2022 | March 2025 | Allow | 30 | 2 | 0 | No | No |
| 17870477 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING AUTOIMMUNE GFAP ASTROCYTOPATHY | July 2022 | June 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 17812537 | BIOMARKERS FOR DIAGNOSING IMPLANT RELATED RISK OF IMPLANT REVISION DUE TO ASEPTIC LOOSENING | July 2022 | September 2024 | Allow | 26 | 2 | 1 | No | No |
| 17851613 | Secreted P-glycoprotein is a Non-Invasive Biomarker of Chronic Rhinosinusitis | June 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17848804 | ASSAY TO DETECT AND QUANTITATE SPECIFIC ANTIBODIES FOR VARIOUS REDOX FORMS OF HMGB1 | June 2022 | June 2024 | Allow | 24 | 1 | 0 | No | No |
| 17824162 | DETECTION REAGENT AND THERAPEUTIC TARGET FOR B CELL TUMOR AFTER TARGETED THERAPY AND RELATED APPLICATION | May 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17745140 | GLUCURONYLATION AS A NEW ACIDIC POST-TRANSLATIONAL MODIFICATION ON THERAPEUTIC MONOCLONAL ANTIBODIES | May 2022 | April 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17743289 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | May 2022 | April 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17735524 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HOST CELL PROTEINS | May 2022 | September 2024 | Allow | 28 | 2 | 0 | No | No |
| 17730403 | DETECTION OF ANTI-p53 ANTIBODIES | April 2022 | December 2023 | Allow | 20 | 2 | 0 | No | No |
| 17715294 | METHODS AND DEVICES FOR QUANTITATIVELY ESTIMATING SYNDECAN-1 | April 2022 | August 2024 | Allow | 28 | 2 | 0 | Yes | Yes |
| 17699706 | Methods of Detecting Anti-folic acid Antibodies and Uses Thereof | March 2022 | February 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17762088 | METHOD FOR ASSIGNING ANTIBODY STANDARD AND DETERMINING MINIMUM DETECTION LIMIT OF ANTIBODY DETECTION REAGENT | March 2022 | February 2023 | Allow | 10 | 1 | 0 | No | No |
| 17695381 | Biomarker Panel for Non-Invasive Diagnosis of Congenital Renal Dysfunction | March 2022 | November 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17693789 | MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE | March 2022 | November 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17684296 | MULTIPLEXED DIAGNOSTIC TO RECOGNIZE CONCENTRATIONS OF RELATED PROTEINS AND PEPTIDES | March 2022 | December 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17679493 | METHOD AND COMPOSITION FOR DETECTION OF PROTEOLYTIC PRODUCTS AND DIAGNOSIS OF MALIGNANT NEOPLASTIC DISEASE | February 2022 | May 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17679640 | CATION EXCHANGE CHROMATOGRAPHY METHODS | February 2022 | July 2024 | Allow | 29 | 3 | 0 | No | No |
| 17676072 | NOVEL TARGETS FOR THE TREATMENT AND DIAGNOSIS OF PATIENTS WITH ATHEROSCLEROSIS AND ENHANCED RISK OF END ORGAN DAMAGE | February 2022 | January 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17668261 | DETECTION OF GLUCURONIDATED AND 3-BROMOTYROSINE | February 2022 | May 2024 | Allow | 27 | 2 | 0 | No | No |
| 17667376 | METHODS FOR DETERMINING AMOUNT OF FUNCTIONAL ALBUMIN | February 2022 | October 2023 | Allow | 21 | 1 | 0 | No | No |
| 17590325 | LATERAL FLOW TEST STRIP READERS, CARTRIDGES AND RELATED METHODS | February 2022 | June 2025 | Allow | 41 | 4 | 1 | Yes | No |
| 17558248 | KITS AND METHODS FOR PREDICTION AND TREATMENT OF PREECLAMPSIA | December 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17534012 | ASSAYS FOR DETECTING THE PRESENCE OR AMOUNT OF AN ANTI-DRUG ANTIBODY | November 2021 | November 2023 | Allow | 23 | 0 | 1 | Yes | No |
| 17525717 | KITS AND METHODS TO DISTINGUISH FALSE LABOR AND TRUE LABOR | November 2021 | October 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17508619 | ASSAY METHOD FOR THE DETECTION OF VCAM-1 AND ALPHA-2-MACROGLOBULIN IN BLOOD | October 2021 | April 2023 | Allow | 18 | 3 | 1 | Yes | No |
| 17490568 | HIGHLY SENSITIVE PARTICLE ENHANCED ASSAY FOR THE QUANTIFICATION OF NT-PROBNP | September 2021 | November 2022 | Allow | 13 | 2 | 1 | No | No |
| 17473747 | METHODS FOR DETERMINING THERAPEUTIC RESPONSIVENESS FOR INFLAMMATORY BOWEL DISEASE THERAPY | September 2021 | March 2025 | Allow | 42 | 1 | 1 | No | No |
| 17470485 | ANTI-CARBAMYLATED PROTEIN ANTIBODIES AND THE RISK FOR ARTHRITIS | September 2021 | September 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17462209 | USE OF MAGNETIC NANOPARTICLES FOR THE DETECTION AND QUANTITATION OF ANALYTE(S) | August 2021 | October 2022 | Allow | 14 | 2 | 1 | Yes | No |
| 17411863 | GDF15 IN GLAUCOMA AND METHODS OF USE THEREOF | August 2021 | November 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17408096 | DETECTING ADAPTIVE IMMUNITY TO CORONAVIRUS | August 2021 | February 2023 | Abandon | 18 | 2 | 1 | No | No |
| 17428416 | COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASE | August 2021 | November 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 17376058 | COMPOSITIONS AND METHODS FOR ASSAYING NEUTRALIZING ANTIBODIES | July 2021 | March 2024 | Allow | 32 | 1 | 1 | No | No |
| 17371025 | Device and Methods | July 2021 | September 2024 | Allow | 38 | 4 | 1 | Yes | No |
| 17367049 | COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAI | July 2021 | April 2024 | Allow | 34 | 3 | 0 | No | No |
| 17353532 | ERYTHROCYTE SIMULATING PARTICLE, PREPARATION METHOD THEREFOR, AND QUALITY CONTROL OR CALIBRATOR CONTAINING SAME | June 2021 | April 2025 | Allow | 46 | 1 | 1 | No | No |
| 17349134 | ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ADRENOMEDULLIN | June 2021 | March 2023 | Allow | 21 | 1 | 0 | No | No |
| 17292109 | METHODS AND SYSTEMS FOR TREATING CANCER BASED ON RESPONSE PREDICTION USING LIGHT SCATTERING TECHNOLOGY | May 2021 | October 2024 | Allow | 41 | 0 | 1 | Yes | No |
| 17290369 | FACTOR XIII IMMUNOASSAY | April 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17288542 | MEANS AND METHOD FOR POINT-OF-CARE ANALYSIS OF LIQUID SAMPLES | April 2021 | March 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17286221 | Biomarkers For A Systemic Lupus Erythematosus (SLE) Disease Activity Immune Index That Characterizes Disease Activity | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17231209 | METHOD FOR ASSISTING PREDICTION OF EXACERBATION OF RESPIRATORY INFECTION, AND DEVICE TO ASSIST IN PREDICTING EXACERBATION OF RESPIRATORY INFECTION | April 2021 | July 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17212360 | System and Method for Disease Surveillance and Disease Severity Monitoring for COVID-19 | March 2021 | June 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17190135 | RGMa Fragment Based Diagnostic Assay | March 2021 | June 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17268337 | METHOD FOR MEASURING THE TRIMETHYLAMINE N-OXIDE PRODUCTION CAPACITY IN AN INDIVIDUAL | February 2021 | May 2025 | Allow | 51 | 1 | 1 | No | No |
| 17265393 | METHODS FOR DETECTING ANTI-DRUG ANTIBODIES | February 2021 | April 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17127402 | BEAD-BASED ASSAYS FOR PROTEIN ANALYSIS | December 2020 | February 2024 | Allow | 38 | 2 | 1 | No | No |
| 17056889 | PARAMAGNETIC IMMUNOBEADS FOR THE ISOLATION OF HUMAN ADIPOSE-DERIVED STEM CELLS | November 2020 | February 2025 | Allow | 51 | 3 | 0 | No | No |
| 17055705 | METHODS FOR DETECTING PROSTATE CANCER PATHOLOGY ASSOCIATED WITH ADVERSE OUTCOMES | November 2020 | December 2024 | Abandon | 49 | 1 | 1 | No | No |
| 17097688 | Bio-Fet Sensor Array with Matrix Controlled On-Chip Electrode | November 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17054820 | BLOOD BIOMARKERS OF STROKE | November 2020 | November 2024 | Allow | 48 | 2 | 1 | No | No |
| 17093461 | BIOCHEMICAL PREDICTORS OF RED BLOOD CELL QUALITY | November 2020 | September 2023 | Allow | 34 | 1 | 0 | Yes | No |
| 17088237 | METHODS OF SCREENING FOR SORTILIN BINDING ANTAGONISTS | November 2020 | September 2024 | Allow | 47 | 3 | 0 | Yes | No |
| 17087103 | MONOCLONAL ANTIBODIES SPECIFICALLY FOR THE ANTIGEN P OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS, PRODUCED AND SECRETED BY THE CELLS HYBRIDOMAS, USEFUL FOR DETECTION AND DIAGNOSTIC OF THE INFECTION CAUSED BY RSV | November 2020 | September 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 16641951 | MEANS AND METHOD FOR DETECTING ANALYTES BY MEANS OF MACROSCOPIC GRANULATE PARTICLES | October 2020 | December 2024 | Abandon | 57 | 3 | 1 | Yes | No |
| 17080533 | PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION | October 2020 | July 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17075470 | Method, Systems, and a Kit for Detection, Diagnosis, Monitoring and Treatment of COVID-19 | October 2020 | February 2023 | Abandon | 28 | 4 | 1 | Yes | No |
| 17046984 | SCREENING ASSAYS AND KITS FOR CHARACTERIZING AN ABILITY OF A CANDIDATE COMPOUND TO MODULATE A BINDING AFFINITY BETWEEN AN FBW7 PROTEIN AND AN FBW7 SUBSTRATE | October 2020 | July 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17065631 | METHOD AND APPARATUS FOR MONITORING THE STATE OF HEALTH OF DAIRY COWS | October 2020 | September 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17063673 | METHOD OF DETERMINING COMPOSITION EFFECTIVE FOR TREATING DIABETES | October 2020 | May 2023 | Allow | 31 | 2 | 1 | No | No |
| 17036739 | METHOD OF DIAGNOSING HEART MUSCLE DAMAGE | September 2020 | January 2025 | Abandon | 52 | 2 | 1 | No | No |
| 16975482 | BIOMARKERS FOR UROLOGIC CHRONIC PELVIC PAIN SYNDROME | August 2020 | April 2024 | Abandon | 43 | 0 | 1 | No | No |
| 16971705 | COMPOUNDS AND METHODS FOR THE DETECTION OF FABRY DISEASE | August 2020 | July 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16971286 | QUANTITATIVE ANALYSIS OF PROTEINS | August 2020 | January 2025 | Allow | 53 | 2 | 0 | Yes | No |
| 16996281 | METHODS OF DETECTING ANTI-LEPTIN NEUTRALIZING ANTIBODIES | August 2020 | March 2023 | Allow | 30 | 0 | 1 | Yes | No |
| 16918911 | METHOD FOR RE-USING TEST PROBE AND REAGENTS IN AN IMMUNOASSAY | July 2020 | January 2024 | Abandon | 43 | 1 | 1 | No | No |
| 16954918 | ANGPTL8 ASSAY AND USES THEREOF | June 2020 | February 2024 | Allow | 44 | 1 | 1 | No | No |
| 16954935 | Detection of Autoantibodies for Diagnosing Degenerative Diseases of the Skeletal System | June 2020 | November 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16946328 | Method and products for the diagnosis of a seafood allergy | June 2020 | September 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16899629 | CIRCULATING ANGIOPOIETIN-2 (ANG-2) AND INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7 (IGFBP7) FOR THE PREDICTION OF STROKE | June 2020 | May 2023 | Allow | 35 | 3 | 1 | Yes | No |
| 16771413 | LABEL-FREE OPTICAL DETECTION IN CAPTURE ZONES IMMOBILIZED ON STRIPS FOR LATERAL FLOW ASSAYS | June 2020 | August 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16888252 | SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRY | May 2020 | February 2024 | Allow | 44 | 1 | 1 | No | No |
| 16766337 | METHOD AND DEVICE FOR DISCRIMINATING BETWEEN VIRAL AND BACTERIAL INFECTIONS | May 2020 | November 2022 | Abandon | 30 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COUNTS, GARY W.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COUNTS, GARY W works in Art Unit 1678 and has examined 455 patent applications in our dataset. With an allowance rate of 66.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner COUNTS, GARY W's allowance rate of 66.6% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by COUNTS, GARY W receive 2.17 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by COUNTS, GARY W is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.8% benefit to allowance rate for applications examined by COUNTS, GARY W. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.6% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 27.0% of cases where such amendments are filed. This entry rate is in the 29% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 78.8% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 84.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 51.1% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.